JP6460991B2 - 抗菌剤として使用するための三環式ジャイレース阻害剤 - Google Patents

抗菌剤として使用するための三環式ジャイレース阻害剤 Download PDF

Info

Publication number
JP6460991B2
JP6460991B2 JP2015532025A JP2015532025A JP6460991B2 JP 6460991 B2 JP6460991 B2 JP 6460991B2 JP 2015532025 A JP2015532025 A JP 2015532025A JP 2015532025 A JP2015532025 A JP 2015532025A JP 6460991 B2 JP6460991 B2 JP 6460991B2
Authority
JP
Japan
Prior art keywords
group
membered
compound
ring
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015532025A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015528502A5 (OSRAM
JP2015528502A (ja
Inventor
ベンセン，ダニエル
ボーチャード，アレン
チェン，ツィヨン
フィン，ジョン，エム．
ラム，タン，ト
リー，スク，ジョン
リ，シャオミン
タリ，レスリ，ウィリアム
テン，ミン
トロゾス，マイケル
ツァン，ジュンフ
ジュン，マイケル，イー．
ライトストーン，フェリス，シー
ウォン，セルジオ，イー．
ニュエン，トーン，ビー．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of JP2015528502A publication Critical patent/JP2015528502A/ja
Publication of JP2015528502A5 publication Critical patent/JP2015528502A5/ja
Application granted granted Critical
Publication of JP6460991B2 publication Critical patent/JP6460991B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2015532025A 2012-09-12 2013-09-11 抗菌剤として使用するための三環式ジャイレース阻害剤 Active JP6460991B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261700159P 2012-09-12 2012-09-12
US61/700,159 2012-09-12
PCT/US2013/059310 WO2014043272A1 (en) 2012-09-12 2013-09-11 Tricyclic gyrase inhibitors for use as antibacterial agents

Publications (3)

Publication Number Publication Date
JP2015528502A JP2015528502A (ja) 2015-09-28
JP2015528502A5 JP2015528502A5 (OSRAM) 2016-11-04
JP6460991B2 true JP6460991B2 (ja) 2019-01-30

Family

ID=49226575

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015532025A Active JP6460991B2 (ja) 2012-09-12 2013-09-11 抗菌剤として使用するための三環式ジャイレース阻害剤

Country Status (7)

Country Link
US (1) US10865216B2 (OSRAM)
EP (1) EP2895488B1 (OSRAM)
JP (1) JP6460991B2 (OSRAM)
CN (1) CN105189505B (OSRAM)
AR (1) AR092538A1 (OSRAM)
TW (1) TWI639602B (OSRAM)
WO (1) WO2014043272A1 (OSRAM)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2651417B1 (en) 2010-12-16 2016-11-30 Calchan Limited Ask1 inhibiting pyrrolopyrimidine derivatives
US9732083B2 (en) * 2011-03-15 2017-08-15 Merck Sharp & Dohme Corp. Tricyclic gyrase inhibitors
EP4545530A1 (en) 2013-09-11 2025-04-30 Merck Sharp & Dohme LLC Tricyclic gyrase inhibitors
WO2016067009A1 (en) * 2014-10-28 2016-05-06 Redx Pharma Plc Compounds with activity against bacteria and mycobacteria
CA3024273A1 (en) 2016-06-01 2017-12-07 Universite De Montreal Selection of human hematopoetic stem cells using epcr
CN106588731B (zh) * 2016-12-08 2018-06-29 河北桑迪亚医药技术有限责任公司 环丙基二苯基锍三氟甲磺酸盐的合成方法
EP3604281A4 (en) 2017-03-24 2020-08-19 Taisho Pharmaceutical Co., Ltd. 2(1h)-quinolinone derivative
JP7344125B2 (ja) 2017-03-30 2023-09-13 エフ． ホフマン－ラ ロシュ アーゲー 細菌感染の治療及び予防のための新規ピリド［２，３－ｂ］インドール化合物
KR102559705B1 (ko) 2017-05-04 2023-07-25 바이엘 크롭사이언스 악티엔게젤샤프트 예를 들어 식물의 보호를 위한 해충-방제제로서의 2-｛[2-(페닐옥시메틸)피리딘-5-일]옥시｝-에탄아민-유도체 및 관련 화합물
US11542248B2 (en) * 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
US11649251B2 (en) 2017-09-20 2023-05-16 Kura Oncology, Inc. Substituted inhibitors of menin-MLL and methods of use
EP3755355A4 (en) 2018-02-20 2022-01-05 Universite De Montreal Expansion of nk and dc cells in vivo mediating immune response
JP7443351B2 (ja) * 2018-09-26 2024-03-05 エフ． ホフマン－ラ ロシュ アーゲー 細菌感染症の治療及び予防のための、置換ピリドインドール
WO2020085493A1 (ja) 2018-10-26 2020-04-30 大鵬薬品工業株式会社 新規なインダゾール化合物又はその塩
WO2020127624A1 (en) * 2018-12-20 2020-06-25 F. Hoffmann-La Roche Ag Oxopyrido[1,2-a]pyrimidine compounds for the treatment and prophylaxis of bacterial infection
WO2020225077A1 (en) * 2019-05-03 2020-11-12 Idorsia Pharmaceuticals Ltd Pyrimido[4,5-b]indol derivatives as pdhk1 inhibitors
PE20221253A1 (es) 2019-10-28 2022-08-16 Merck Sharp & Dohme Inhibidores de pequenas moleculas de mutante g12c de kras
US12479834B2 (en) 2019-11-29 2025-11-25 Taiho Pharmaceutical Co., Ltd. Phenol compound or salt thereof
CN112574085A (zh) * 2020-12-18 2021-03-30 南通药明康德医药科技有限公司 一种5-氨基-2-氮杂螺[3.4]辛烷-2-羧酸叔丁酯的制备方法
CN112552222B (zh) * 2020-12-18 2022-08-23 南通药明康德医药科技有限公司 一种2-(2-(叔-丁氧羰基)-2-氮杂螺[3.4]辛烷-5-基)乙酸的制备方法
CN114763357B (zh) * 2021-01-15 2024-06-18 中国科学院上海药物研究所 吲哚并嘧啶三环类化合物及其制备方法和用途
CN113372352B (zh) * 2021-06-10 2022-08-26 青岛农业大学 吲哚3,4位并九元中环化合物及其制备方法
WO2024064726A1 (en) * 2022-09-21 2024-03-28 Bristol-Myers Squibb Company Process for the preparation of tert-butyl (2-azabicyclo[2.2.1]heptan-4-yl)carbamate and related compounds
EP4615847A1 (en) * 2022-11-11 2025-09-17 Merck Sharp & Dohme LLC Small molecule inhibitors of kras proteins
WO2024233776A1 (en) * 2023-05-09 2024-11-14 Merck Sharp & Dohme Llc Small molecule inhibitors of kras g12d mutant
TW202535891A (zh) 2023-10-20 2025-09-16 美商默沙東有限責任公司 Ｋｒａｓ蛋白之小分子抑制劑
WO2025240742A1 (en) * 2024-05-15 2025-11-20 Merck Sharp & Dohme Llc Protein degraders of kras g12d mutant

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN157280B (OSRAM) 1983-07-15 1986-02-22 Hoechst India
DE4030059A1 (de) 1990-09-22 1992-03-26 Bayer Ag Verfahren zur herstellung von 5-hydroxy-3,4,5,6-tetrahydro-pyrimidin-derivaten
DE4032560A1 (de) 1990-10-13 1992-04-16 Bayer Ag 7-(2,7-diazabicyclo(3.3.0)octyl)-3-chinolon- und -naphtyridoncarbonsaeure-derivate
US5279359A (en) 1992-06-26 1994-01-18 Erickson Donald C Rotary trisorption heat pump
US5527910A (en) 1992-12-30 1996-06-18 Cheil Foods & Chemicals, Inc. Pyridone carboxylic acid compounds and their uses for treating infectious diseases caused by bacteria
KR20020067701A (ko) 2000-01-24 2002-08-23 워너-램버트 캄파니 3-아미노퀴나졸린-2,4-디온 항균제
US20090099165A1 (en) 2003-10-14 2009-04-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
US20090143399A1 (en) 2003-10-14 2009-06-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
ES2344007T3 (es) * 2003-10-14 2010-08-16 The Arizona Board Of Regents On Behalf Of The University Of Arizona Inhibidores proteina quinasa.
US20080051414A1 (en) 2003-10-14 2008-02-28 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
US7776855B2 (en) 2006-07-27 2010-08-17 Janssen Pharmaceutica N.V. Antimicrobial oxazolidinone prodrugs
EP2475666A2 (en) 2009-09-11 2012-07-18 Trius Therapeutics, Inc. Gyrase inhibitors
US9732083B2 (en) * 2011-03-15 2017-08-15 Merck Sharp & Dohme Corp. Tricyclic gyrase inhibitors
EP4545530A1 (en) * 2013-09-11 2025-04-30 Merck Sharp & Dohme LLC Tricyclic gyrase inhibitors

Also Published As

Publication number Publication date
AR092538A1 (es) 2015-04-22
EP2895488B1 (en) 2024-12-11
CN105189505B (zh) 2019-03-22
WO2014043272A1 (en) 2014-03-20
EP2895488A1 (en) 2015-07-22
TW201425314A (zh) 2014-07-01
US10865216B2 (en) 2020-12-15
JP2015528502A (ja) 2015-09-28
CN105189505A (zh) 2015-12-23
US20150246934A1 (en) 2015-09-03
TWI639602B (zh) 2018-11-01

Similar Documents

Publication Publication Date Title
JP6460991B2 (ja) 抗菌剤として使用するための三環式ジャイレース阻害剤
JP6140083B2 (ja) 三環式ジャイレース阻害薬
US12234235B2 (en) Salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
KR102447084B1 (ko) Trk 키나제 억제제로서의 거대 고리 화합물 및 그의 용도
EP2475666A2 (en) Gyrase inhibitors
JP2022511112A (ja) Ａｌｋ５阻害剤としてのナフチリジンおよびキノリン誘導体
TW202330519A (zh) 作為ｔａｍ抑制劑的吡唑并吡啶化合物
EP4448521A1 (en) Reversible macrocyclic kinase inhibitors
IL319215A (en) Preparations for administering JAK kinase inhibitors
NZ614983B2 (en) Tricyclic gyrase inhibitors
HK1198164B (en) 3,5-disubstituted alkynylbenzene compound and salt thereof

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20160217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160909

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160909

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20161108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161108

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20161114

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170720

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A132

Effective date: 20170801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171113

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180829

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180912

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20180914

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181204

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181225

R150 Certificate of patent or registration of utility model

Ref document number: 6460991

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313115

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250